Rev Med Brux. 2008 Sep-Oct;29(5):455-70.
The present guidelines on the management of extensive disease small cell lung cancer (SCLC) were formulated by the European Lung Cancer Working Party (ELCWP) in October 2007. They are designed to answer the following nine questions : 1) What is the definition of extensive disease? 2) What are the active drugs? 3) What is the best induction regimen? 4) Is there a role for maintenance chemotherapy? 5) Is there a role for dose-intensive chemotherapy? 6) Is there a role for the use of haematopoietic growth factors and stem cells support? 7) Is there a role for alternating or sequential chemotherapy? 8) Is there a role for biological treatments? 9) Is there a place for second-line chemotherapy ?
目前关于广泛期小细胞肺癌(SCLC)管理的指南由欧洲肺癌工作组(ELCWP)于2007年10月制定。它们旨在回答以下九个问题:1)广泛期疾病的定义是什么?2)有哪些活性药物?3)最佳诱导方案是什么?4)维持化疗是否有作用?5)剂量密集化疗是否有作用?6)使用造血生长因子和干细胞支持是否有作用?7)交替或序贯化疗是否有作用?8)生物治疗是否有作用?9)二线化疗是否有地位?